Evidence map›Paper›PMID 38299345›Full record

ArticleCirculation. Heart failure2024

Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure With Preserved Ejection Fraction.

Joe David Azzo, Marie-Joe Dib, Loukas Zagkos, Lei Zhao, Zhaoqing Wang, Ching-Pin Chang, Christina Ebert, Oday Salman, Sushrima Gan, Payman Zamani and 14 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation. Heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
9.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Proteomic Risk Score for Prediction of Incident Hypertension.Hypertension (Dallas, Tex. : 1979) · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Clinical Insights from Proteomics in Heart Failure.Current heart failure reports · 2025
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 10 institutions in 8 countries.

Joe David Azzo *University of Pennsylvania Perelman School of Medicine, Philadelphia (J.D.A., O.S., P.Z., T.P.C., J.A.C.).
Marie-Joe Dib *Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (M.-J.D., S.G., P.Z., T.P.C., J.A.C.).ORCID 0000-0001-7591-5684
Loukas ZagkosDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, United Kingdom (L.Z., D.G.).ORCID 0000-0002-7700-8102
Lei ZhaoBristol Myers Squibb Company, Lawrenceville, NJ (L.Z., Z.W., C.-P.C., C.E., J.B.C., P.S., D.A.S., F.R.-V., D.A.G.).ORCID 0000-0001-7099-3712
Zhaoqing WangBristol Myers Squibb Company, Lawrenceville, NJ (L.Z., Z.W., C.-P.C., C.E., J.B.C., P.S., D.A.S., F.R.-V., D.A.G.).ORCID 0000-0003-1515-4945
Ching-Pin ChangBristol Myers Squibb Company, Lawrenceville, NJ (L.Z., Z.W., C.-P.C., C.E., J.B.C., P.S., D.A.S., F.R.-V., D.A.G.).
Christina EbertBristol Myers Squibb Company, Lawrenceville, NJ (L.Z., Z.W., C.-P.C., C.E., J.B.C., P.S., D.A.S., F.R.-V., D.A.G.).
Oday SalmanUniversity of Pennsylvania Perelman School of Medicine, Philadelphia (J.D.A., O.S., P.Z., T.P.C., J.A.C.).ORCID 0000-0002-8390-1036
Sushrima GanDivision of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (M.-J.D., S.G., P.Z., T.P.C., J.A.C.).
Payman ZamaniUniversity of Pennsylvania Perelman School of Medicine, Philadelphia (J.D.A., O.S., P.Z., T.P.C., J.A.C.).ORCID 0000-0002-9345-5834
Jordana B CohenBristol Myers Squibb Company, Lawrenceville, NJ (L.Z., Z.W., C.-P.C., C.E., J.B.C., P.S., D.A.S., F.R.-V., D.A.G.).ORCID 0000-0003-4649-079X
Vanessa van EmpelDepartment of Cardiology, Maastricht University Medical Center, the Netherlands (V.v.E.).ORCID 0000-0002-6864-0296
A Mark RichardsCardiovascular Research Institute, National University of Singapore (A.M.R.).ORCID 0000-0002-2023-8177
Ali JavaheriWashington University School of Medicine, St. Louis, MO (A.J., D.L.M.).ORCID 0000-0001-6657-331X
Douglas L MannWashington University School of Medicine, St. Louis, MO (A.J., D.L.M.).ORCID 0000-0002-2516-0145
Ernst R RietzschelDepartment of Cardiovascular Diseases, Ghent University Hospital, Belgium (E.R.).ORCID 0000-0002-8422-177X
Peter H SchaferBristol Myers Squibb Company, Lawrenceville, NJ (L.Z., Z.W., C.-P.C., C.E., J.B.C., P.S., D.A.S., F.R.-V., D.A.G.).
Dietmar A SeiffertBristol Myers Squibb Company, Lawrenceville, NJ (L.Z., Z.W., C.-P.C., C.E., J.B.C., P.S., D.A.S., F.R.-V., D.A.G.).
Dipender GillDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, United Kingdom (L.Z., D.G.).ORCID 0000-0001-7312-7078
Stephen BurgessDepartment of Public Health and Primary Care, University of Cambridge, United Kingdom (S.B.).ORCID 0000-0001-5365-8760
Francisco Ramirez-ValleBristol Myers Squibb Company, Lawrenceville, NJ (L.Z., Z.W., C.-P.C., C.E., J.B.C., P.S., D.A.S., F.R.-V., D.A.G.).ORCID 0000-0002-8625-5869
David A GordonBristol Myers Squibb Company, Lawrenceville, NJ (L.Z., Z.W., C.-P.C., C.E., J.B.C., P.S., D.A.S., F.R.-V., D.A.G.).ORCID 0000-0001-9882-8372
Thomas P CappolaUniversity of Pennsylvania Perelman School of Medicine, Philadelphia (J.D.A., O.S., P.Z., T.P.C., J.A.C.).
Julio A ChirinosUniversity of Pennsylvania Perelman School of Medicine, Philadelphia (J.D.A., O.S., P.Z., T.P.C., J.A.C.).ORCID 0000-0001-9035-5670
Bristol-Myers Squibb (Belgium) · BEHospital of the University of Pennsylvania · USUniversity of Pennsylvania · USWashington University in St. Louis · USBristol-Myers Squibb (Germany) · DEGhent University Hospital · BEImperial College London · GBMaastricht University Medical Centre · NLNational University of Singapore · SGUniversity of Cambridge · GB

Funding

Subclinical Vascular Contributions to Alzheimer's Disease: The Multi-Ethnic Study of Atherosclerosis (MESA) Multisite Study of AD (Renewal)R01AG058969 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Timothy M. Hughes, YONGMEI LIU · 2018 to 2026
$33.4M
Understanding the relationship between obesity and tongue fat in humans and ratsP01HL094307 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI PACK, ALLAN I · 2009 to 2020
$23.7M
Predicting Weight Regain Following Weight Loss Using Physiological Measures of Appetite and Energy ExpenditureUH3DK128298 · NIDDK · DREXEL UNIVERSITY · PI KELLY C ALLISON, MATTHEW R HAYES · 2022 to 2026
$6.8M
Genomics of myocardial transcription factors in cardiac remodelingR01HL088577 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CAPPOLA, THOMAS P. · 2007 to 2013
$5.3M
MTSS1 in Myocardial DiseaseR01HL141232 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI THOMAS P. CAPPOLA, Scott Michael Damrauer · 2019 to 2026
$4.7M
VASCULAR EFFECTS OF DIETARY SALT IN HUMANS WITH SALT-RESISTANT BPR01HL104106 · NHLBI · UNIVERSITY OF DELAWARE · PI EDWARDS, DAVID G, FARQUHAR, WILLIAM B · 2011 to 2021
$4.5M
NAD+ precursor supplementation with exercise training to improve aerobic capacity in Friedreich's AtaxiaR01HL149722 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI MCCORMACK, SHANA ERIN · 2020 to 2024
$4.0M
Targeting Skeletal Muscle Perfusion and Oxidative Capacity in HFpEFR01HL155599 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI ZAMANI, PAYMAN · 2021 to 2025
$3.9M
Multidrug Metabolic Approach to Improve Exercise and Skeletal Muscle Oxidative Capacity in HFpEFR01HL157264 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI ZAMANI, PAYMAN · 2021 to 2025
$3.5M
Blockade of calcium channels and beta adrenergic receptors for physiologic abnormalities in heart failure with preserved ejection fraction (BLOCK HFpEF)R01HL153646 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI COHEN, JORDANA B. · 2020 to 2024
$3.2M
Efficacy of Potassium Nitrate in Heart Failure with Preserved Ejection FractionR01HL121510 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CHIRINOS MEDINA, JULIO ALONSO · 2015 to 2019
$3.1M
Developing Oral LT3 Therapy for Heart FailureR33HL146390 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CAPPOLA, ANNE R, CAPPOLA, THOMAS P. · 2020 to 2022
$2.2M
NHLBI NIH HHS K23 HL133843NHLBI NIH HHS P01 HL094307NHLBI NIH HHS R01 HL088577NHLBI NIH HHS R01 HL104106NHLBI NIH HHS R01 HL121510NHLBI NIH HHS R01 HL141232NHLBI NIH HHS R01 HL149722NHLBI NIH HHS R01 HL153646NHLBI NIH HHS R01 HL155599NHLBI NIH HHS R01 HL157264NHLBI NIH HHS R03 HL146874NHLBI NIH HHS R33 HL146390NHLBI NIH HHS R56 HL136730NHLBI NIH HHS U01 HL160277NIA NIH HHS K24 AG070459NIA NIH HHS R01 AG058969NIDDK NIH HHS UH3 DK128298Wellcome Trust 100114
6 · The paper itself

Abstract

backgroundNT-proBNP (N-terminal pro-B-type natriuretic peptide) levels are variably elevated in heart failure with preserved ejection fraction (HFpEF), even in the presence of increased left ventricular filling pressures. NT-proBNP levels are prognostic in HFpEF and have been used as an inclusion criterion for several recent randomized clinical trials. However, the underlying biologic differences between HFpEF participants with high and low NT-proBNP levels remain to be fully understood.

methodsWe measured 4928 proteins using an aptamer-based proteomic assay (SOMAScan) in available plasma samples from 2 cohorts: (1) Participants with HFpEF enrolled in the PHFS (Penn Heart Failure Study; n=253); (2) TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial) participants in the Americas (n=218). We assessed the relationship between SOMAScan-derived plasma NT-proBNP and levels of other proteins available in the SOMAScan assay version 4 using robust linear regression, with correction for multiple comparisons, followed by pathway analysis.

resultsNT-proBNP levels exhibited prominent proteome-wide associations in PHFS and TOPCAT cohorts. Proteins most strongly associated with NT-proBNP in both cohorts included SVEP1 (sushi, von Willebrand factor type-A, epidermal growth factor, and pentraxin domain containing 1; β

conclusionsCirculating NT-proBNP levels exhibit prominent proteomic associations in HFpEF. Our findings suggest that higher NT-proBNP levels in HFpEF are a marker of fibrosis and inflammation. These findings will aid the interpretation of NT-proBNP levels in HFpEF and may guide the selection of participants in future HFpEF clinical trials.

Indexed as

Heart FailureNatriuretic Peptide, BrainBiomarkersFibrosisHumansInflammationPeptide FragmentsPrognosisProteomicsStroke VolumeBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)biomarkersfibrosisheart failureinflammationproteomics

Identifiers

PMID38299345
PMCPMC7615693
OpenAlexW4391448127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.